Literature DB >> 9548396

Preventive effects of the deleted form of hepatocyte growth factor against various liver injuries.

H Masunaga1, N Fujise, A Shiota, H Ogawa, Y Sato, E Imai, H Yasuda, K Higashio.   

Abstract

The effects of a naturally occurring deleted form of hepatocyte growth factor (HGF) on hepatic disorder were studied in various models of hepatic failure. The pretreatment of rats and mice with the deleted form of HGF prevented the liver injuries and coagulopathy induced by endotoxin, dimethylnitrosamine and acetaminophen and reduced the mortality due to hepatic dysfunction induced by these hepatotoxins. The concurrent administration of the deleted form of HGF also prevented the liver injury and hepatic fibrosis in mice treated with alpha-naphthylisothiocyanate and in rats treated with dimethylnitrosamine. Moreover, the deleted form of HGF normalized the results of the bromosulphalein-clearance test and ameliorated jaundice in rats with periportal cholangiolitic hepatopathy induced by alpha-naphthylisothiocyanate. The deleted form of HGF also reversed the coagulopathy in rats with hepatic disorder induced by dimethylnitrosamine or by 70% resection of cirrhotic liver (induced by carbon tetrachloride). In Long Evans cinnamon rats receiving vehicle, 20 out of 21 animals died within 4 days after the onset of jaundice. After infusion of the deleted form of HGF for 4 days, 7 out of 20 Long-Evans cinnamon rats survived. These results indicate that the deleted form of HGF could have therapeutic potency in patients with severe hepatic failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548396     DOI: 10.1016/s0014-2999(97)01485-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation.

Authors:  F Xue; T Takahara; Y Yata; M Minemura; C Y Morioka; S Takahara; E Yamato; K Dono; A Watanabe
Journal:  Gut       Date:  2002-04       Impact factor: 23.059

2.  High-level expression and characterization of bioactive human truncated variant of hepatocyte growth factor in Escherichia coli.

Authors:  Xiaohua Wang; Haifeng Liu; Zhongmin Zhang; Yang Liu; Yuting Li; Jinqiu Gui; Yanhui Chu
Journal:  World J Microbiol Biotechnol       Date:  2014-08-14       Impact factor: 3.312

Review 3.  Promising protein biomarkers in the early diagnosis of Alzheimer's disease.

Authors:  Lalit Sharma; Aditi Sharma; Deepak Kumar; Manish Kumar Asthana; H Lalhlenmawia; Ashwani Kumar; Sanjib Bhattacharyya; Deepak Kumar
Journal:  Metab Brain Dis       Date:  2022-01-11       Impact factor: 3.655

Review 4.  Advances in antifibrotic therapy.

Authors:  Zahra Ghiassi-Nejad; Scott L Friedman
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-12       Impact factor: 3.869

5.  Improvement of sepsis by hepatocyte growth factor, an anti-inflammatory regulator: emerging insights and therapeutic potential.

Authors:  Shinya Mizuno; Toshikazu Nakamura
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

Review 6.  HGF-Met Pathway in Regeneration and Drug Discovery.

Authors:  Kunio Matsumoto; Hiroshi Funakoshi; Hisaaki Takahashi; Katsuya Sakai
Journal:  Biomedicines       Date:  2014-10-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.